Current as of May 17, 2024

Short Talks Selected from Proffered Abstracts

PR01 **EZH2 inhibitors improve CAR-T therapy by enhancing lymphoma B cell immunogenicity and CAR-T cell functions.** Yusuke Isshiki. Weill Cornell Medicine, New York, NY, United States.

PR02 **Aging-associated molecular and cellular alterations determine the biology and clinical characteristics of DLBCL in elderly patients.** Nahuel Zamponi. Weill Cornell Medicine, Manhattan, NY, United States.

PR03 **Immunosurveillance of precancerous germinal center B cells.** Dinis Pedro Parente Calado. The Francis Crick Institute, London, United Kingdom.

PR04 **Characterization of an essential MYC enhancer targeted by focal genomic alterations in diffuse large B-cell lymphoma.** Aishwarya Gurumurthy. University of Michigan, Ann Arbor, MI, United States.

PR05 **Single-cell transcriptomics reveals shared and subtype-specific vulnerabilities of the tumor-microenvironment ecosystems in peripheral T-cell lymphomas.** Wen-Hsuan Wendy Lin. Columbia University Irving Medical Center, New York, NY, United States.

PR06 **Comprehensive characterization of the non-tumor microenvironment of relapsed/refractory large B-cell lymphoma identifies patients with greatest benefit from CD19 CAR T-cell therapy.** Xubin Li. UT MD Anderson Cancer Center, Houston, TX, United States.

PR07 **SETD1B mutations confer apoptosis resistance and BCL2 independence in B-cell lymphoma.** Ana Portelinha. Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Poster Session (To be presented on June 20 from 5:30-7:30 p.m. ET)

**CAR T-cells and T-cell Engagers**

**PO-001** GPR65-low tumor clones reprogram macrophage via VEGF signaling and confer antigen-independent CAR-T resistance. Jayadev Mavuluri. St.Jude Children's Research Hospital, Memphis, TN, United States.

**PO-002** Intrinsically disordered regions -induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers. Xinyan Zhang. Yale University, New Haven, CT, United States.

**PO-003** Peripheral blood and tumor tissue biomarkers associated with epcoritamab response in patients with relapsed or refractory diffuse large B-cell lymphoma: Data from the dose-expansion cohort of the phase 1/2 EPCORE NHL-1 trial (NCT03625037). Monica Wielgos-Bonvallet. Genmab, Plainsboro, NJ, United States.

**PO-004** EZH2 inhibitors improve CAR-T therapy by enhancing lymphoma B cell immunogenicity and CAR-T cell functions. Yusuke Isshiki. Weill Cornell Medicine, New York, NY, United States.

**PO-005** Mechanistic models of cancer heterogeneity explain and predict clinical outcomes of Large B-Cell Lymphoma (LBCL) treatment. Amy Pomeroy. University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

**Chemotherapy-free Management and Treatment**


**PO-007** A phase 1 study of romidepsin, azacitidine, dexamethasone, and lenalidomide (RAdR) for relapsed/refractory T-cell malignancies. Max Gordon. NCI, Bethesda, MD, United States.

**Clinical Trials (including Trials in Progress)**

**PO-008** Phase I/II study of VIP152 (enitociclib), venetoclax, and prednisone (VVIP) in relapsed/refractory (R/R) lymphoid malignancies. Christopher Melani. National Cancer Institute, Bethesda, MD, United States.

**PO-009** AC676 a BTK Chimeric Degrader: Phase 1 study in patients with B-cell Malignancies. Manish Patel. Florida Cancer Specialists, Sarasota, FL, United States.

Epigenetics

PO-011 **SETD1B mutations confer apoptosis resistance and BCL2 independence in B-cell lymphoma.** Ana Portelinha. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

PO-012 **Gain-of-function small molecules to reprogram oncogenic transcription in lymphoma.** Sai Gourisankar. Stanford University, Stanford, CA, United States.

PO-013 **Combined epigenetic therapy to induce latency II/III antigen expression in latency I EBV lymphoma.** Isabella Kong. Weill Cornell Medicine, New York, NY, United States.

PO-014 **Characterization of an essential MYC enhancer targeted by focal genomic alterations in diffuse large B-cell lymphoma.** Aishwarya Gurumurthy. University of Michigan, Ann Arbor, MI, United States.

Genomics

PO-015 **The RNA helicase DDX21 cooperates with ETS1 and FLI1 in cell cycle regulation, immune evasion and small nucleolar RNA processing to sustain the survival of DLBCL cells.** Giulio Sartori. Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

PO-016 **Test-the-test: Clinical utility of comprehensive whole exome sequencing (WES) and RNA-seq for lymphoma patients.** Krystle Nomie. BostonGene, Corp., Boston, MA, United States.

Germinal Center Biology

PO-017 **Immunosurveillance of precancerous germinal center B cells.** Dinis Pedro Parente Calado. The Francis Crick Institute, London, United Kingdom.

Lymphomagenesis

PO-018 **Commensal bacteria are required for chronic inflammation and B lymphoma development in myeloid cell-specific TRAF3-deficient mice.** Ping Xie. Rutgers University, Piscataway, NJ, United States.

PO-019 **Ubiquitin E3 ligase OSTM1 regulates the cAMP/PKA/CREB pathway and suppresses B-cell malignancies.** Muhammad Usama Tariq. Rutgers University, Piscataway, NJ, United States.

PO-020 **ZBTB24 is a novel tumor suppressor and cooperates with CDKN2A to suppress B-cell lymphomagenesis.** Rongrong Li. Rutgers University, Piscataway, NJ, United States.

PO-021 **Modeling marginal zone lymphomagenesis.** Victor Yazbeck. Massey Cancer Center, Richmond, VA, United States.
Microenvironment

PO-022 **Distinct intratumoral microbiome signatures enrichment in patients with different Anaplastic Large Cell Lymphoma (ALCL) subtypes.** Paola Ghione. Memorial Sloan Kettering Cancer Center, NEW YORK CITY, NY, United States.

PO-023 **CD70 deregulation in follicular lymphoma at diagnosis is associated with relapse and opens new avenues for dual CD19-CD70 CAR-T therapy.** Ferran Araujo-Ayala. IDIBAPS, Barcelona, Spain.

PO-024 **Single-cell transcriptomics reveals shared and subtype-specific vulnerabilities of the tumor-microenvironment ecosystems in peripheral T-cell lymphomas.** Wen-Hsuan Wendy Lin. Columbia University Irving Medical Center, New York, NY, United States.

PO-025 **Identifying tissue-specific drivers of immune evasion in Mantle Cell Lymphoma at single cell level.** Amira Marouf. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

PO-026 **Comprehensive characterization of the non-tumor microenvironment of relapsed/refractory large B-cell lymphoma identifies patients with greatest benefit from CD19 CAR T-cell therapy.** Xubin Li. UT MD Anderson Cancer Center, Houston, TX, United States.

PO-028 **A high-throughput bone marrow 3D co-culture system to develop resistance to targeted agents in marginal zone lymphoma.** Alex Zadro. Institute of Oncology Research, Bellinzona, Switzerland.

PO-029 **Aging-associated molecular and cellular alterations determine the biology and clinical characteristics of DLBCL in elderly patients.** Nahuel Zamponi. Weill Cornell Medicine, Manhattan, NY, United States.

PO-030 **Single cell spatial analysis of large B cell lymphoma identifies biomarkers correlated with genetic subtypes and clinical outcomes.** Akil Merchant. Cedars-Sinai Medical Center, Los Angeles, CA, United States.

Other

PO-031 **Systematic discovery of chemotherapy response biomarkers in Peripheral T Cell Lymphomas.** Jacob Pantazis. UNC at Chapel Hill, Chapel Hill, NC, United States.

PO-032 **A novel strategy to overcome resistance of diffuse large B-cell lymphoma to venetoclax.** Francesco Ciccarese. Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.

PO-034 **Targeting metabolic plasticity and flexibility via SIRT3 inhibition to restrain nucleotides availability in DLBCLs.** Meng Li. Weill Cornell Medicine, New York, NY, United States.

**Signaling**

PO-035 **Genome-wide CRISPR knockout screen identifies sialylation as a tumor suppressive mechanism in B-cell malignancies.** Namratha Sheshadri. Rutgers - The State University of New Jersey, Piscataway, NJ, United States.

PO-036 **Targeting the CBM signalosome with a MALT1 scaffolding inhibitor for treatment of non-Hodgkin lymphomas.** Kevin Ling. HotSpot Therapeutics, Boston, MA, United States.

PO-037 **Machine learning-enabled transomics identifies three therapeutic targets for MYC-driven diffuse large B cell lymphoma.** Simon Fricker. Pepper Bio, Cambridge, MA, United States.

**Tumor Immunology**

PO-038 **Unbiased discovery of novel antibody therapies that stimulate macrophage-mediated destruction of B-cell lymphoma.** Juliano Ribeiro. Whitehead Institute for Biomedical Research, Cambridge, MA, United States.

PO-040 **Mechanisms of action of immune checkpoint blockade therapy in EZH2/Bcl2-mutant B-cell lymphomas.** Alexey Sarapulov. Weill Cornell Medical College, New York, NY, United States.